Clinical-stage biopharmaceutical company Inotek Pharmaceuticals Corporation announced earlier today that the results from its Phase 1 dose-escalation trial in healthy adult volunteers of the Company’s lead product candidate, trabodenoson, have been published in the Journal of Ocular Pharmacology and Therapeutics (JOPT).
The results reportedly support Inotek's ongoing clinical development of trabodenoson as a novel treatment for glaucoma, and follow publication of the Phase 2 study in patients with primary open-angle glaucoma (POAG) or ocular hypertension (OHT), announced on April 11, 2016.
The research article, “A Randomized Phase 1 Dose Escalation Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Trabodenoson in Healthy Adult Volunteers,” presents data showing that ocular doses of trabodenoson up to 3,200 µg per eye were safe and well tolerated both in the eye and systemically in healthy adult volunteers.
Click here to read the full press release.
Source: Inotek Pharmaceuticals Corporation